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ABSTRACT
Acute myeloid leukemia (AML) is a malignancy that is often found in children. Many studies into the failure of
apoptosis function, or programmed cell death, is one of the most important regulatory mechanisms of cellular
hemostasis which is closely linked to the development of cancer, are important.  Also, regulation of the apoptotic
(p53) and anti-apoptotic (surviving) proteins influence treatment outcome.  One role of p53 is to monitor cellular
stress necessary to induce apoptosis. Surviving (BIRC5) is a group of proteins in the apoptosis inhibitor which
works by inhibiting caspase-3. The role of surviving is considered very important in oncogenesis proliferation and
cell growth regulation. Chemotherapy in childhood AML can inhibit cell growth and induce slowing as well as
stopping the cell cycle. Thus, the aim of this study was to compare p53 and surviving before and after receiving
induction chemotherapy in children with AML and also to determine the p53/surviving ratio. Peripheral blood
mononuclear cells were collected from AML children before treatment and three months after starting their induc -
tion therapy. p53 and surviving were measured by flowcytometry using monoclonal antibodies. Data were ana-
lyzed by t-test for comparison between groups and Spearman’s test to find out the correlation between variables
with a significant value of p < 0.05. A total of 8 children were evaluated. The intensity of p53 expression was not
significantly increased after induction phase chemotherapy (p = 0.224), but surviving expression and the ratio of
p53/surviving were significantly increased in the treatment group compared with the levels prior to chemotherapy
(p = 0.002, p = 0.034), and there was a strong negative correlation between p53 and surviving after chemotherapy
(r = −0.63, p = 0.049).   
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Leukemia is  a malignant  disease in children with
the highest incidence between the ages of 2-5 years [1]
and is the most malignancy in children with an inci-
dence of 4-4.5 cases/year/100,000 [2]. In Europe, in the
period between 1988 -1997, acute leukemia incidence
was 22.6 per one million of which 15% was AML. In
Germany, the proportion of AML was 13% while in
the US, it was 16%.  In Yogyakarta, the incidence of
ALL  was  20.8/1,000,000  while  for  AML  it  was
8/1,000,000.  AML mainly occurs from 2-5 years [3].
But AML Treatment has made much progress in devel-
oped countries with success reaching 65%, whereas, in
Indonesia, it is expected to remain below 10% [3].  
The mechanism of apoptosis, which is a process of
cell  death,  attempts  to remove unwanted and excess
cells.  Thus,  apoptosis  is  important  for  protection
against pathogens and tissue homeostasis [4].
One role of p53 is to monitor for cellular stress and
for its resulting damage which can be severe and ir-
reparable.  Tumor  suppressors  act  to  maintain  tissue
homeostasis and to control the number and behavior
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of cells in certain tissues and p53 is a suppressor that
has been widely studied which acts in response to vari-
ous forms of cellular stress and is involved in approxi-
mately  50% of  human cancers  [5].  The  loss  of  p53
function causes genomic instability and increased mu-
tagenesis, and it is thought that the mutation of p53 is
one  of  the  factors  that  cause  cancer  resistance  to
chemotherapy [6]. 
Surviving (BIRC5) is  a therapeutic target because
its expression occurs during the development of malig-
nancy and its role is considered to be important both
in oncogenesis and in cell proliferation and growth reg-
ulation  [7].  Physiologically,  surviving  is  detected  in
high levels in the fetal period, but declines as the fetus
develope.  When  the  surviving  level  was  increase,  it
should be correlates with the incidence of relapse and
treatment  failure  and  the  low life  expectancy of  pa-
tients with AML[7, 8].
The  expression  of  surviving  in  solid  tumors  has
seen many studies and in theory, there is a relationship
between p53 as a pro-apoptosis and surviving as an in-
hibitor of apoptosis [8]. Thus, this research hoped it
could be used as a reference for the ratio of p53/surviv-
ing that can be used as a prognostic marker for AML
treatment in children. AML chemotherapy in children
can result in DNA damage which can stimulate p53 to
inhibit surviving expression [9].
 Therefore, the aim of this study was to measure
the ratio p53/surviving to investigate its use as a pa-
rameter in the induction phase chemotherapy response
in children with acute myeloid leukemia.
The study used a study design with a pre and post-
experiment  approach  (cohort  study).  Sampling  was
done by consecutive  sampling  and this  research  was
conducted at the Department of Pediatrics Dr. Saiful
Anwar Hospital,  Malang and the Biomedical Labora-
tory of the Faculty of Medicine, Brawijaya University.
Sampling was conducted from March 2015 to August
2015, and the subjects were patients under treatment in
the Department of Pediatrics Dr. Saiful Anwar Malang
Hospital.  The criteria for the diagnosis  of  AML was
based on morphological analysis of bone marrow punc-
tures. The study subjects were then divided into com-
plete  remission,  partial  remission  and  no  remission
groups.  Informed consent  was  obtained from all  the
relevant parents.
Criteria for the inclusion of cases was: 1. AML pa-
tients, 2.post induction phase chemotherapy 3. age be-
low 14 years,  4.informed consent  from relevant  par-
ents, and the exclusion criteria were: 1. patients with
drug withdrawal during the induction phase of chemo-
therapy and 2. autoimmune diseases, such as SLE and
myasthenia  gravis.  This  study has  been approved by
the Ethics Committee of Saiful Anwar Hospital.
Peripheral blood mononuclear cells (PBMC) were
isolated from EDTA blood by Ficoll-Hypaque density
gradient centrifugation. Intracellular staining of protein
was performed according to the manufacturer’s instruc-
tions. Phycoerythrin (PE) labeled anti-surviving mono-
clonal antibodies were provided by R&D System Inc.
(catalog  #:IC6472P),  and  fluorescein  isothiocyanate
(FITC)  labeled  p53  monoclonal  antibodies  were  ob-
tained from Santacruz (catalog #:sc7272FITC). Briefly,
cells were incubated in the dark at 18-240C for 15 min-
utes. Cells were treated with a cell staining buffer in
each sample and centrifuged at 500 G for 5 minutes.
Then, the Cells then were fixed by fixation buffer in
the dark at 18-240C for 20 minutes and centrifuged at
500 G for 5 minutes.  Cell  pellets were washed with
permeabilization  buffer.  They  were  then  incubated
with a cocktail of FITC p53 and PE anti-surviving in
the dark at room temperature for 30 minutes. All the
labeled cells were resuspended in 0.5 mL cell staining
buffer and analyzed by flowcytometry using the FAC-
SCalibur instrument (Becton Dickinson) and the Cell
Quest  software  package  (Becton  Dickinson).  In  this
study, data analysis techniques were calculated in three
stages, respectively: (1) Normality test of data samples
with Shapiro-Wilk test, (2) T-test was done for com-
parison between groups (3)  Spearman’s  Test  to  find
out the correlation between variables. Statistical analy-
sis of data was performed by  SPSS software for  Win-
dows 22.0. The data are presented as mean ± standard
deviations.
All  research  subjects  had  been  diagnosed  with
AML, then the expression levels of p53 and surviving
were examined. After which, the subjects were admin-
istered  the  appropriate  chemotherapy  by  TRAP/
COAP/POMP protocols conducted by standard operat-
ing  procedures  of  the  Hematology-oncology  Depart-
ment in Saiful Anwar Hospital.  The induction phase
was carried out over three months, and then bone mar-
row puncture was re-done to see the results of chemo-
therapy  response  (complete  remission,  partial  remis-
sion or no remission). Expressions of p53 and surviv-
ing were obtained by using flowcytometry conducted at
the  Biomedical  Laboratory,  Brawijaya  University.  All
eight children  received induction  phase chemotherapy
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and their levels of p53 and surviving were noted and
before and after the chemotherapy.
The results are shown in Table 1. 
Study  results  indicated  that  50% of  subjects  suf-
fered from type M4 AML, 37.5% had type M2 AML,
and 12.5% suffered from type M1 AML. After being
given the induction phase chemotherapy,  7 out of 8
(88%) experienced complete remission and 1 out of 8
(12%) experienced partial remission.
Based on flowcytometry figures, the expressions of
p53  and  surviving  were  analyzed  and  the  ratio  of
p53/surviving calculated (Table 2). The p53 expression
was processed by descriptive analysis and paired T-test.
In all 8 of the research subjects, comparative values ob-
tained were p53 -> R2 = 3.24% so that it can be inter-
preted that chemotherapy affects approximately 3.24%
of p53 expression. The significance level of the effect of
chemotherapy on p53 was p = 0.224 (p > 0.05), the ex-
pression of p53 after the induction phase chemother-
apy was not significantly increased. 
Comparison of the results of paired T-test, found
that surviving -> R2 = 62.25%, chemotherapy affected
62.25%. The significance level of the effect of chemo-
therapy on surviving was p = 0.02 (p < 0.05) and the
expression  of  surviving  after  the  induction  phase
chemotherapy was significantly decreased. 
A  paired  T-test  obtained  a  comparative  ratio  of
p53/surviving  before  and  after  induction  phase  of
chemotherapy with a value of p = 0.034 (p < 0.05). i.e.
the p53/surviving ratio after  induction phase chemo-
therapy was significantly increased. 
Spearman correlation test obtained a correlation co-
efficient of -0.63, which means that this study’s results
found a strong correlation with the direction of a nega-
tive correlation: the higher the variable of the p53 ex-
pression, the lower the surviving expression. The result
obtained from the Spearman correlation test indicated
a significance value of p=0.049 (p <0.05), i.e. a negative
one.
Based on Table 3,  the study subjects  showed in-
creased levels of p53 after their chemotherapy. How-
ever,  the p53 expression had increased but not signifi-
cantly because one subject had decreased levels of p53
after the induction phase chemotherapy. In networks
where stressors produce severe damage which can not
be repaired, p53 can initiate apoptosis so as to elimi-
nate the damaged cells [10]. Also, tumor suppressors
act to maintain tissue homeostasis to control the num-
ber and behavior of cells in the body. p53 is a much-
studied  tumor  suppressor  which  acts  in  response  to
various forms of cellular stress to mediate antiprolifera-
tive processes. Therefore, p53 can be activated by DNA
damage, hypoxia or aberrant expression of oncogenes
that drive changes in the cell cycle, DNA repair, cellu-
lar  senescence,  and apoptosis.  By the p53’s  potential
role in modulating cancer  chemotherapy,  the loss  of
p53  function  is  associated  with  chemotherapy  resis-
tance in certain tumor types [11]. Thus, for a complete
understanding  of  the  apoptotic  program it  is  hoped
that research into p53 will lead to better diagnoses and
thus to better prognoses as well as to improvements in
therapy [10, 12].
In this study there was one sample which was not
consistent with the hypothesis, decreased levels of p53
after the induction phase chemotherapy. It was proba-
bly caused by the complexity of the apoptotic pathways
themselves  [10].  The  inhibition  of  proteosome  can
cause decreased p53 levels  together  with the overex-
pression of surviving that is mediated by MDM-2 cas-
pase.  This  explains  that  homologous of p53 such as
DNp63, Tap73, dan DNp73 in mRNA are related to
surviving levels [13]. There are two main pathways of
apoptosis, first, the extrinsic pathway (death receptor
pathways)  and  second,  the  intrinsic  pathway  (mito-
chondrial pathways). These two pathways end with the
activation  of  caspase  (the  enzyme  that  effects  cell
death) [12, 14]. Lose of p53 function related to chemo-
therapy resistence in several tumor types. 
The stimulation of receptor death cells will result in
aggregation and the recruitment of adaptor Fas-associ-
ated protein with death domain (FADD) and caspase-
8. After which, the caspase-8 will be activated and start
the process of apoptosis by the caspase effector [15]. 
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The  Mitochondria  is  involved  in  intrinsic  pathways
through stress stimulation including UV radiation, C-
radiation, heat,  DNA damage, oncoprotein activators,
chemotherapy and p53 [13, 16]. The permeability of
mitochondrial membranes depends on the stability of
the activity between pro-apoptoses such as sitokrom c,
Smac/Diablo,  Omi/HtrA2  (caspase-dependent),  AIF
and Endo G (non-caspase-dependent) and anti-apopto-
sis protein such as Bcl2 (Bax, Bak, Bcl2 dan Bcl-XL,
Mcl-1) [17]. p53 plays a role in the regulation of pro-
apoptosis in the nucleus.
The initiator caspase can directly activate pro-cas-
pase-3 or other executor caspase that result in apopto-
sis. Also, the initiator caspase can activate Bid, a pro-
tein that can react with the mitochondrial membrane
to  stimulate  cytochrome-c  which  activates  caspase-9
and caspase-3 [18].
Chemotherapy  initiates  apoptosis  pathways  both
extrinsically  and  intrinsically,  and  chemotherapeutic
agents which cause DNA damage activate p53 from the
inhibition of MDM-2 [19]. In the extrinsic pathway,
p53 enables to capture of the death receptor signal, fur-
ther  inducing  procaspase-8  to  caspase-8  and  procas-
pase-3 into caspase-3 to trigger apoptosis. In the intrin-
sic pathway, the mitochondrial membrane permeability
is regulated by a balance between protein proapoptosis
(Bid and Bax) and antiapoptosis proteins (Bcl-2) [16]
[20]. The activation of Bax, caspase-2 tBid and leads to
impaired  mitochondrial  membrane  permeability  and
the release of cytochrome-c which then activates  the
apoptotic cascade. Cytochrome-c binds to procaspase-9
and Apaf-1 to activate caspase-9. Also, inhibition of the
Bcl-2 action, also causes p53 to inhibit surviving (in-
hibitor  of  apoptosis  proteins)  so  that  the  process  of
apoptosis via caspase-9 and caspase-3 continues. Cas-
pase-12, which is activated by the endoplasmic reticu-
lum stress,  causes  direct  activation  of  caspase-9  and
then activates caspase-3 as an effector caspase [21]. A
study by Hui et al., 2010, found that the presence of a
positive correlation between the levels of surviving and
p53 in cases  of liver  malignancy [22],  the results  of
which were also similar to those of a study by Baytekin
et  al.,  2011,  in  kidney  malignancies  (renal  cell  ca)
which discovered high levels of surviving in cases resis-
tant to chemotherapy [23].
Based  on  Table  4,  all  study subjects  showed  de-
creased  expressions  of  surviving  after  the  induction
phase chemotherapy, this is significant and conforms
to the hypothesis of this study. Significant levels of sur-
viving have been found in patients with such cancers
like lung, genito-urinary, stomach, colon, liver, pancre-
atic and soft tissue cancers [24]. An increase in the ex-
Table 3. p53  expression  before  and  after  induction  phase
chemotherapy
Chemotherapy p53 expression p-value CI 95%
Before chemotherapy 59.7 ± 21.6 0.224 41.6
After chemotherapy 72.3 ± 19.9
Table 4. Surviving  expression before and after  the  induction
phase chemotherapy
Chemotherapy Surviving expression p-value CI 0.9%
Before chemotherapy 73.4 ± 20.6 0.002 56.2
After chemotherapy 50.6 ± 14.9
Table 5. The p53/surviving ratio before and after the induc-
tion phase chemotherapy.
Chemotherapy p53/surviving ratio p-value CI 09%
Before chemotherapy 0.83 ± 0.25 0.034 0.62
After chemotherapy 1.64 ± 0.96
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Table 2. p53 and surviving expression results before and after the induction phase chemotherapy.
















1 56.38 99.28 96.16 55.26 0.58 1.79
2 62.21 86.74 59.41 38.20 1.04 2.27
3 45.14 79.85 44.23 22.01 1.02 3.62
4 56.18 77.61 58.20 48.49 0.96 1.6
5 60.53 63.75 80.45 68.57 0.75 0.93
6 72.71 79.54 99.86 63.54 0.73 1.25
7 99.92 55.92 89.04 58.05 1.12 0.96
8 24.58 35.40 60.20 53.54 0.4 0.66
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pression of surviving in various malignancies correlates
with the incidence of relapse and treatment failure and
the low life expectancy of patients with AML [25]. 
Surviving is a protein that can be expressed on a
regular or cell neoplasms and controls deregulation of
tumorigenicity.  The  regulation  of  surviving  itself  is
usually dependent on cell cycles.  At the time of cell
proliferation, surviving can be expressed at the G2/M
phase  and then rapidly  decreases  to  a  resting  phase
(G1 phase) [13, 26]. Furthermore, surviving is modu-
lated to promote the cycle-dependent elements (CDE)
and the cycle homology region (CHR) where the pro-
moter is located in the transcription of G2 phase [13]
[26,  27].  Moreover,  surviving  can  be  affected  by
changes in RNA (siRNA) or by a suppressor surviving
(YM155)  where  surviving  will  increase  cell  death
through  the  p53  dependent  apoptosis  pathway  [28].
Thus,  the  early  detection  of  surviving  levels  will  be
very beneficial to both a treatment and prognosis.
Table 5 shows that the ratio of p53/surviving after
the induction phase chemotherapy in AML patients in-
creased significantly which was confirmed the hypothe-
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Figure 1. p53 and surviving expression and  the p53/surviving ratio to induction phase  chemotherapy in children with AML
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sis of the study. 
All AML patients’ response to the treatment were
very varied due to prognostic factors and characteristics
of AML malignancy, patients (age, clinical course and
karyotype), etc. The treatment of AML has made much
progress and in developed countries treatment success
has reached 65% while in Indonesia is expected to re-
main below 10% [3, 29]. Apoptosis abnormalities ac-
celerate the transformation and lead to the prolifera-
tion of  tumors  toward malignancy.  Also,  changes  in
the pathway of tumor suppressor genes and activation
of proto-oncogenes that can play a role in cancer devel-
opment  especially  with  the  deregulation  of  pro-
grammed cell death [30, 31].
Surviving levels can identify the presence of sup-
pression by p53 (wild-type), either directly or indirectly
[32] and low levels of surviving caused by the role of
p53 (wild-type) dependent  apoptosis.  Thus,  both the
expression of surviving and p53 can describe a syner-
gism regarding determining the prognosis in the case
of AML in children [33, 34].
The problems in this study were when patients did
not turn up for scheduled chemotherapy and when pa-
tients did not come for follow-up check-ups on time,
then some patients dropped outs while undergoing the
induction phase chemotherapy. Another problem was
fatalities while undergoing chemotherapy as well as pa-
tients with absolute neutrophil counts (ANC) of less
than  500  so  that  the  necessitating  improvements  in
their general health first. However, none of the obsta-
cles and constraints above affected the results. The lim-
ited number of samples in this study may have affected
the results statistically, but with it is hoped that they
will be of use as a reference for similar studies in the
future and it is also hoped that these findings will con-
tribute to prove that the expression of p53, surviving
and the P53/surviving ratio could be used as a marker
in  the  prognosis  for  chemotherapy  in  children  with
AML.
Expressions of p53 did not increased significantly
after  the  induction  phase  chemotherapy  in  children
with AML,  whereas  the  expressions  of  surviving  de-
creased  significantly  after  the  induction  phase.  The
p53/surviving ratio increased significantly after induc-
tion phase of chemotherapy in children with AML. A
negative correlation was found between the p53 and
surviving expressions in children with AML after in-
duction phase chemotherapy. In this case, p53/surviv-
ing ratio can be use as parameter for induction phase
chemotherapy in children with AML. 
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